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BACKGROUND: The 5-year overall survival (OS) rate remains at 50% for patients with locally advanced head and neck squamous cell 
carcinoma (LAHNSCC), thereby underscoring the need for improved treatments. An antidiabetic agent, metformin, was found in retro-
spective studies to improve survival in patients with HNSCC. Therefore, the authors conducted a phase 1 dose escalation study combin-
ing metformin with chemoradiotherapy in patients with LAHNSCC. METHODS: Nondiabetic patients with LAHNSCC were enrolled in the 
current study to receive escalating doses of metformin and CRT based on the modified toxicity probability interval design. Metformin 
cohort doses included 2000 mg, 2550 mg, and 3000 mg daily in divided doses in addition to cisplatin (at a dose of 100 mg/m2 on days 
1, 22, and 43) and standard radiotherapy (70 grays). Adverse events were categorized as per the National Cancer Institute Common 
Terminology Criteria for Adverse Events (version 4.03). RESULTS: Twenty patients were enrolled, 2 of whom withdrew consent. The 
median age of the patients was 56 years and the majority were male (83%), were white (88%), had p16-positive disease (72%), and were 
tobacco users (61%). The median length of metformin exposure was 28.5 days. The most common grade ≥3 toxicities were nausea (11%), 
vomiting (11%), mucositis (6%), acute kidney injury (17%), anemia (6%), and leukopenia (11%). Dose-limiting toxicities included diarrhea 
and acute kidney injury. After a median follow-up of 19 months, the 2-year overall survival and progression-free survival rates were 90% 
and 84%, respectively. No hypoglycemia events or lactic acidosis were observed. Cisplatin administration did not appear to affect met-
formin pharmacokinetics. The maximum tolerated dose for metformin could not be determined given the limited number of patients who 
tolerated metformin during chemoradiotherapy. CONCLUSIONS: To the authors’ knowledge, the current study is the first phase 1 trial 
combining metformin with chemoradiotherapy. Rates of overall survival and progression-free survival were encouraging in this limited 
patient population, and warrant further investigation in a phase 2 trial. Cancer 2020;126:354-362. © 2019 American Cancer Society. 
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INTRODUCTION
According to the Surveillance, Epidemiology, and End Results (SEER) database, approximately 65,000 new cases of head 
and neck cancer are estimated to be diagnosed in the United States in 2019, with nearly 16,500 patient deaths expected 
this year.1 Early-stage head and neck squamous cell carcinomas (HNSCCs) often are curable with single-modality treat-
ment. However, approximately 60% of newly diagnosed patients present with locally advanced HNSCC (LAHNSCC) 
(American Joint Committee on Cancer eighth edition stage III or IV disease).2 For patients who are unable to undergo 
surgery or who prefer organ preservation, available treatment options include concurrent chemotherapy and radiother-
apy (CRT) or sequential induction chemotherapy followed by RT.3 In a randomized phase 3 trial (Radiation Therapy 
Oncology Group [RTOG] 0522) comparing RT plus cisplatin with or without cetuximab for patients with stage III to IV 
HNSCC, the 2-year progression-free survival (PFS) rate was approximately 65% and the 2-year overall survival (OS) rate 
was approximately 80%.4 Moreover, a previous meta-analysis of randomized controlled trials demonstrated that adding 
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chemotherapy to RT does improve PFS and OS, but 
only with a 5-year survival rate of approximately 50%,4,5 
thereby underscoring the need for improved regimens.
Metformin (1,1-dimethylbiguanide hydrochloride) is 
an oral drug commonly used to treat patients with type 
2 diabetes mellitus, polycystic ovary syndrome, and met-
abolic syndrome.6 Animal models have proven metformin 
to work by inhibiting the mammalian target of rapamy-
cin (mTOR) pathway along with an increase in the phos-
phorylation of 5’ AMP-activated protein kinase (AMPK), 
leading to an antitumor effect.7 Epidemiological studies 
that analyzed either all patients with head and neck can-
cer or those with laryngeal cancer have demonstrated that 
diabetic patients who are treated with metformin not only 
presented with earlier stage disease but had better outcomes 
when compared with diabetic patients who did not receive 
metformin.8,9 Rego et al conducted a systematic review that 
demonstrated that metformin causes cell cycle arrest in the 
G0/G1 phase and apoptosis of cancer cells, thereby giving 
insight into possible mechanisms of metformin-mediated 
anticancer effects.6 In addition, a “window of opportunity 
trial” in which metformin was administered to patients 
between the performance of biopsy and definitive surgical 
resection at a dose of 1000 mg twice daily demonstrated 
that metformin promoted apoptosis as well as increased 
stromal markers of metabolism (eg, caveolin-1 [CAV1] and 
B-galactosidase [GALBG]).10 The impact of metformin 
on the metabolic milieu of the tumor microenvironment, 
especially its ability to reduce the level of hypoxia, is of 
special interest and has been explored in preclinical stud-
ies.11,12 This metabolic effect of metformin also is believed 
to be the mechanism by which the sensitivity of tumor tis-
sue to PD-1–blocking drugs increases, thereby laying the 
foundation for clinical trials combining metformin with 
immunotherapy drugs such as pembrolizumab.13 In lung 
cancer cell lines, metformin also has been shown to be an 
effective radiosensitizer.14 Given the anticancer proper-
ties of metformin due to its metabolic effects as well as its 
radiosensitization effects, we conducted a phase 1, open- 
label, single-site dose escalation study combining met-
formin with CRT in patients with LAHNSCC.
MATERIALS AND METHODS
Patients
Eligible patients were aged ≥18 years with histologically 
or cytologically confirmed, newly diagnosed, locally ad-
vanced stage III or stage IV HNSCC (T1-T2, N2a-N3, 
or T3-T4 according to the American Joint Committee 
on Cancer seventh edition) and an Eastern Cooperative 
Oncology Group performance status ≤1, and had 
adequate organ function. Exclusion criteria included 
patients with nasopharyngeal cancer, metastatic disease, 
or diabetes requiring insulin or receipt of metformin 
within the last 4 weeks; those with a history of other 
active intercurrent illnesses (eg, significant cardiovascular 
disease, viral infections, or major psychiatric illness); and 
patients receiving medications with the potential to in-
duce lactic acidosis.
Study Design and Treatment
The current study was a single-center, open-label, non-
randomized phase 1 dose escalation trial of metformin 
in combination with CRT in previously untreated 
patients with LAHNSCC. The clinical trial was regis-
tered on Clini calTr ials.gov (Clini calTr ials.gov identifier 
NCT02325401). The study was approved by the insti-
tutional review board at the University of Cincinnati and 
was conducted in accordance with Good Clinical Practice 
guidelines and the Declaration of Helsinki. Written 
informed consent was received from all participating 
patients prior to study enrollment.
Radiotherapy
All patients were treated with standard-of-care RT, which 
entailed 70 grays (Gy) to macroscopic disease with mar-
gin and a simultaneous integrated boost of 56 Gy to areas 
at risk of microscopic disease, all delivered in 35 frac-
tions. An optional, intermediate-dose volume of 63 Gy 
was allowed based on physician discretion to entail areas 
believed to be at higher risk of disease recurrence. Because 
all patients were treated with RT in the same fashion, the 
RT is believed to have had no bearing on outcomes or 
metformin-related toxicity.
Chemotherapy
Patients were treated with institutional standard-of-care 
bolus cisplatin (100 mg/m2 on days 1, 22, and 43) with 
intravenous hydration administered on the day of treat-
ment and 2 days subsequently. Mannitol was added for 
those patients with central line access. Antiemetic pre-
medications were used including a 5-HT3 antagonist, 
corticosteroids, and fosaprepitant. For acute nausea and 
vomiting, supportive care was given at the discretion of 
the treating investigator.
Metformin dose escalation phase
Cohorts of patients received escalating doses of metformin 
(2000 mg, 2550 mg, or 3000 mg divided into daily doses) 
with a 7-day to 14-day lead-in prior to CRT based on the 
modified toxicity probability interval design15 (Fig. 1) to 
allow for possible re-escalation after previous de-escalation 
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Figure 1. (A) Clinical trial schema. Eligible patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) 
(American Joint Committee on Cancer seventh edition stage III/IV) were consented to receive metformin during a lead-in period of 
7 days (patients 1 to 7) or 14 days (from patient 8 onward). (B) The dose was escalated slowly to the allotted cohort dose over the 
lead-in period and then continued at the cohort dose during chemoradiotherapy. The starting dose of metformin was 2000 mg daily 
in divided doses in addition to cisplatin at a dose of 100 mg/m2 on days (D) 1, 22, and 43 along with concurrent radiotherapy (2 grays 
[Gy] per day 5 days per week for a total of 70 Gy). A fall-back dose of 1000 mg daily (cohort 1) was included but not required during 
the study. Blood draws (indicated by black boxes) were performed on day -14, day 1, and subsequently while receiving treatment 
during week 3 and at the completion of treatment for pharmacodynamics. Pharmacokinetic (PK) blood draws were performed on 
day -14 and day 1 at 0, 0.5, 1, 2, 4, and 24 hours. Under the initial protocol, patients 1, 5, 6, and 7 were enrolled in cohort 1 and patients 
2 to 4 were enrolled in cohort 2. Under the amendment, patients 8 and 9 were enrolled in cohort 1, patients 10 to 12 and 18 to 21 were 
enrolled in cohort 2, and patients 13 to 17 were enrolled in cohort 3. (C) Schematic for patient dose assignment based on modified 
toxicity probability interval design. The x-axis represents the total number of patients in each cohort and the y-axis represents the 
total number of patients with ≥1 dose-limiting toxicities (DLTs) recorded at that dose level. The shaded area represents the first 
3 patients in the first cohort. “E” would result in escalation to the next cohort. “D” indicates de-escalation to the prior dose, “S” 
indicates that the next patient is to stay at the current dose, and “DU” indicates unacceptable toxicity and therefore no patients 
could be escalated back to this dose for the remainder of the study. However, the next patient could be de-escalated to the next 
lower dose until no further cohorts were available. The dose received by the majority of patients was confirmed to be the maximum 
tolerated dose (MTD). BID indicates twice daily; TID, 3 times a day.
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and to maximize the ability to identify the maximum toler-
ated dose (MTD). Patients continued to receive metformin 
for the duration of CRT as tolerated. The study initially 
was designed to allow for a 7-day lead-in of metformin 
in which metformin was increased after 3 days to the full 
cohort dose, but, due to the occurrence of nausea with 
accelerated escalation to the full cohort dose, the study was 
amended (from patient 8 onward) to allow for a lead-in of 
14 days and slower escalation to the cohort dose. During 
the lead-in period, patients were started on oral metformin 
at a dose of 500 mg twice daily on day -14 (day -7 for 
the initial amendment) (Fig. 1). They then were continued 
on this dose or were escalated to their final cohort dose of 
3 times a day on day -3. The starting dose of metformin 
was 2000 mg daily in divided doses and the highest dose 
was 3000 mg daily. Metformin was taken with meals and 
withheld for 48 hours for any contrast scans. Patients were 
instructed to check their blood glucose on a daily basis. 
Metformin also was withheld for creatinine >1.5 mg/dL 
or a glomerular filtration rate (GFR) of <30 mL/minute.
Dose-limiting toxicity
The dose-limiting toxicity (DLT) was defined as the 
appearance of side effects during treatment that were 
severe enough to prevent further increases in the dose of 
metformin or to prevent the continuation of standard-
of-care treatment at any dose level. DLTs were defined as 
metformin-related grade 3 or 4 nonhematologic toxicities 
other than alopecia, nausea, or vomiting, or those toxicities 
that the investigator determined were possibly, probably, 
or definitely related to metformin rather than standard-
of-care treatment. Patients were considered evaluable for 
toxicity if they completed ≥3 doses of metformin. DLTs 
were assessed until 2 weeks after the completion of RT.
Three patients were enrolled into a cohort. The fre-
quency of DLTs per cohort determined into which cohort 
the subsequent patients would be enrolled (Fig. 1). If no 
DLTs were identified, then up to 3 patients were enrolled 
at the next cohort level. However, if 2 total DLTs were 
experienced in any cohort level at any time during the 
process, the subsequent patients were to be enrolled into 
cohorts of 1 patient each until DLTs were assessed for all 
patients. The phase 1 portion was not considered com-
plete until all 18 evaluable patients had been enrolled or 
the number of observed DLTs had resulted in an unac-
ceptable dose at the lowest dose level.
Assessments
The primary endpoint of the current study was to 
determine the MTD of metformin in combination with 
CRT for patients with LAHNSCC. Key secondary end-
points included the evaluation of adverse events (AEs) 
(graded as per the National Cancer Institute Common 
Terminology Criteria for Adverse Events [version 4.03]), 
the evaluation of PFS and OS at 2 years, and the effect 
of cisplatin pharmacokinetics (PKs) on the tolerability of 
metformin. Safety and tolerability assessments were con-
ducted at the time of study visits, at the end of treatment, 
and during follow-up. After the completion of treatment, 
patients were followed monthly for the first 3 months 
and then every 3 months for the first year followed by 
every 6 months for 2 years for survival until death or 
withdrawal of consent. Patients were required to undergo 
positron emission tomography/computed tomography at 
12 weeks to document treatment response.
Pharmacokinetics
For PK analysis, serial blood samples were collected at 
0, 0.5, 1, 2, 4, and 24 hours after the administration of 
metformin on day -7 or day -14 and day 1. Metformin 
plasma levels were quantitated using a liquid chromatog-
raphy–mass spectrometry method. The Thermo Fisher 
Scientific LTQ FT Ultra mass spectrometer, a hybrid 
 mass spectrometer consisting of a linear ion trap and a 
Fourier-transform ion cyclotron resonance mass spectrom-
eter, was used for the detection of met formin. Metformin 
was separated from other analytes by reverse phase chro-
matography using a Waters XBridge Amide column 
(2.1 mm × 100 mm, 3.5 μm). The composition of the 
mobile phase was 25:75 (95:5 water:acetonitrile 0.1% 
HCOOH; and 95:5 acetonitrile:water 0.1% HCOOH). 
Metformin and the deuterated internal standard met-
formin-d6 hydrochloride (Toronto Research Chemicals) 
were detected by multiple reaction monitoring of the 
130.11 m/z → 60 m/z and 136.15 m/z → 60 m/z quan-
tifying transitions for metformin and metformin-d6 
hydrochloride, respectively. PK analysis was performed 
using noncompartmental analysis (Phoenix 64 Win-
Nonlin; Certara USA Inc).
Correlative Pharmacodynamics
Blood samples were obtained for pharmacodynam-
ics as shown in Figure 1. Samples were processed by a 
Clinical Laboratory Improvement Amendments (CLIA)– 
certified clinical laboratory for the determination of glu-
cose, lactate levels (to document any signs of developing 
lactic acidosis), vitamin B12 (given that long-term use of 
metformin has been associated with low vitamin B12 lev-
els),16 and C-peptide levels (to study the impact on pan-
creatic β cells).17
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Statistical Analyses
The dose-finding part of the study was to enroll a maxi-
mum of 18 evaluable patients. The sample size was chosen 
based on the maximum number of patients who could 
have been enrolled on a 3+3 design studying 3 doses. 
Secondary endpoints of safety as assessed by clinical review 
of AEs and laboratory tests were analyzed using appro-
priate summary statistics. Any patient who had received 
≥3 days of treatment with metformin was considered 
evaluable for toxicity. Secondary efficacy endpoints (OS 
and PFS) were analyzed using Kaplan-Meier summary 
statistics. PFS was defined as the duration of time from 
the initiation of treatment to disease progression and OS 
was considered the duration of time a patient was alive 
from the initiation of treatment until the time of death. 
Comparisons of Kaplan-Meier survival data between dif-
ferent subgroups were conducted using the log-rank test. A 
P value <.05 indicated a statistically significant difference 
between the subgroups. For correlative pharmacodynam-
ics analysis, patients’ glucose, vitamin B12, and C-peptide 
levels were measured before administration of metformin, 
before chemotherapy, and off metformin. Measurements 
(before chemotherapy and off metformin) were compared 
with those from before metformin using 2-sample Student 
t tests for paired data. The data cutoff for these analyses was 
October 22, 2018. All statistical analyses were performed 
using R statistical software (version 3.3.3; R Foundation).
RESULTS
Patient Characteristics and Disposition
Between May 11, 2015, and December 26, 2017, a total of 
21 patients were consented with 20 patients enrolled. Two 
patients withdrew consent during the metformin lead-in 
period due to non–DLT-related reasons. The remaining 18 
patients were included for analysis. The median age of the 
cohort was 56 years (range, 46-65 years); the majority of 
the enrolled patients were male (83%) and white (88%). 
Approximately 61% of the patients were tobacco users 
(>10 pack-years). Thirteen patients tested positive for 
p16 expression (the remaining 5 patients either were nega-
tive or did not have p16 analysis completed) (Table 1). In 
approximately 50% of patients, metformin was discontin-
ued or interrupted due to an AE; a total of 10 patients were 
able to remain on metformin during CRT for a sufficient 
period of time (less than one-half the duration of CRT).
Dose Escalation, DLTs, and MTD
Because of early nausea in the lead-in period, the proto-
col was amended after patient 7 to allow for the slower 
TABLE 1. Baseline Patient and Disease 
Characteristics
Patient Characteristics No. (%)  






African American 2 (11%)
Tobacco abusers 11 (61%)
p16 positive 13 (72%)
Primary tumor site    
Oropharynx 12 (67%)
Larynx 6 (33%)
AJCC stage AJCC 7 AJCC 8
I   4 (22%)
II   2 (11%)
III 2 (11%) 8 (44%)
IVA 12 (67%) 4 (22%)
IVB 4 (22%)  
Tumor classification    
T1 or T2 4 (22%) 6 (33%)
T3 or T4 12 (67%) 10 (56%)
Tx 2 (11%) 2 (11%)
Lymph node classification    
N0 2 (11%) 2 (11%)
N1 1 (6%) 5 (28%)
N2a or N2b 6 (33%) 5 (28%)
N2c 6 (33%) 3 (17%)
N3 3 (17%) 3 (17%)
Abbreviations: AJCC, American Joint Committee on Cancer; AJCC 7, 
American Joint Committee on Cancer seventh edition; AJCC 8, American 
Joint Committee on Cancer eighth edition.









Gastrointestinal      
Diarrhea 8 (44%) 7 (39%) 1 (6%)
Nausea 14 (77%) 12 (67%) 2 (11%)
Vomiting 9 (50%) 7 (39%) 2 (11%)
Reflux 5 (28%) 5 (28%) 0
Mucositis 5 (28%) 4 (22%) 1 (6%)
Other (abdominal pain, 
dysphagia, altered taste)
8 (44%) 8 (44%) 0
Metabolism and nutrition 
disorders
     
AKI 8 (44%) 5 (28%) 3 (17%)
Lactic acidosis 0 0 0
Electrolyte abnormalities 4 (22%) 4 (22%) 0
Blood and lymphatic system 
disorders
     
Leukopenia/neutropenia 5 (28%) 3 (17%) 2 (11%)
Anemia 5 (28%) 4 (22%) 1 (6%)
Investigations      
LFT abnormalities 2 (11%) 2 (11%) 0
Ear and labyrinth disorders      
Tinnitus, hearing loss, ear 
pain
4 (22%) 4 (22%) 0
Abbreviations: AKI, acute kidney injury; LFT, liver function test.
aAdverse events were graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (version 4.03).
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escalation of metformin to the cohort dose. Of the evalu-
able patients, approximately 85% experienced ≥1 AEs 
(Table 2). The most common AEs were related to the 
gastrointestinal tract, with nausea observed in 77% of 
the patients followed by vomiting and diarrhea. DLTs 
included grade 3 diarrhea (cohort 3) and acute kidney 
injury (cohort 2), the latter of which occurred prior to the 
initiation of CRT. The most common grade ≥3 toxici-
ties were diarrhea (6%), nausea (11%), vomiting (11%), 
mucositis (6%), acute kidney injury (17%), anemia (6%), 
and leukopenia (11%), the majority of which were related 
to standard-of-care treatment rather than metformin. 
Lactic acidosis was not observed. Based on the modified 
toxicity probability interval design, the MTD for met-
formin could not be determined reliably given the lim-
ited number of patients who tolerated the drug during 
CRT. However, a dose of 2550 mg daily in combination 
with CRT was found to be the highest dose tolerated at 
the highest frequency, suggesting that this dose may be 
acceptable as a recommended phase 2 dose.
Survival Outcomes
After a median follow-up of 19 months, the 1-year OS 
and PFS rates both were 90%. The 2-year OS and PFS 
Figure 2. Kaplan-Meier curves of investigator-assessed (A) progression-free survival (PFS) and (B) overall survival (OS). Hash marks 
indicate censored observations.
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rates were 90% and 84%, respectively (Fig. 2). Two 
deaths were reported during the course of follow-up. One 
patient had a sudden unexplained death within 3 to 
4 days of the completion of CRT; the patient had received 
only 5 days of metformin lead-in. The other patient died 
29 months after the completion of treatment. Both deaths 
were deemed unrelated to metformin and unlikely related 
to disease. One patient experienced disease recurrence 
17 months after the completion of CRT and underwent 
salvage surgical resection and subsequently was free of dis-
ease at the time of last follow-up.
Pharmacodynamics
Blood samples were collected prior to receipt of met-
formin (day -7 or day -14), after metformin lead-in but 
prior to CRT (day 1), and after the completion of therapy. 
Vitamin B12, glucose, C-peptide, and lactate levels were 
measured. No elevations in lactate that were concerning 
for lactic acidosis were observed. In addition, glucose levels 
did not decrease significantly during treatment with met-
formin. An increase in C-peptide was observed after met-
formin lead-in in the majority of patients that returned to 
baseline after treatment, but changes were not statistically 
significant (Fig. 3). It is important to note that vitamin 
B12 levels were decreased by metformin administration 
in the majority of patients and supplementation was 
required in one patient, although this finding was not sta-
tistically significant (Fig. 3). It is interesting to note that 
the vitamin B12 levels returned to above baseline after 
metformin treatment was completed (P < .001).
Archival tissue immunohistochemistry analysis 
revealed activation of the mTOR pathway, suggesting 
that these patients would benefit from mTOR pathway 
inhibitors such as metformin (see Supporting Fig. 1 and 
Supporting Table 1).
Pharmacokinetics
Metformin is excreted primarily unchanged by the kidney, 
with a mean renal clearance (CLR) of 500 mL/minute. 
This indicates that the CLR of metformin is higher than 
the GFR, and active tubular secretion is the principal 
mechanism of metformin elimination.18 Cisplatin is well 
known to cause nephrotoxicity.19 Approximately 50% of 
the cisplatin administered is excreted renally within the 
first 24 hours. As such, the concentration of platinum 
achieved in the renal cortex is several-fold greater than 
that in plasma and other organs.20 Cisplatin primar-
ily injures the S3 segment of the proximal tubule, caus-
ing a decrease in the GFR.21 In fact, its adverse effect on 
kidney function is one of its primary DLTs. Thus, in the 
Figure 3. Metformin effects on laboratory blood levels. Levels of (A) C-peptide and (B) vitamin B12 before (pre) metformin, during 
metformin, and off metformin. Chemo indicates chemotherapy.
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current combination study, the systemic exposure (plasma 
levels and the overall area under the curve) of metformin 
may have been impacted considerably by the coadminis-
tration of cisplatin. The nephrotoxic effects of cisplatin 
potentially could reduce the metformin CLR, resulting in 
an increase in the systemic exposure. Therefore, for those 
patients for whom sufficient blood samples were collected, 
we performed PK studies at multiple time points. It was 
observed that the area under the curve on day 1 did in-
crease with escalation of the metformin dose, as would 
be expected (6181 ± 4340 ng/mL*hour in cohort 1 
compared with 8499 ± 3032 ng/mL*hour in cohort 3) 
(Table 3). Although there was substantial patient intersub-
ject variability, it is important to note that the creatinine 
clearance did not appear to affect acute concentrations 
of metformin in these patients. Longer term effects were 
unable to be analyzed in the current study.
DISCUSSION
In the current study, we have presented the results of a 
phase 1, dose-finding clinical trial of metformin added to 
CRT in patients with LAHNSCC. In previous retrospec-
tive studies and systematic reviews, metformin has been 
suggested to decrease not only the rates of locoregional 
disease recurrence but also the OS among patients with 
HNSCC.22 Several studies have demonstrated the poten-
tial safety and efficacy of metformin in cancers other than 
HNSCC, including rectal cancer, acute lymphoblastic leu-
kemia, and lung cancer.23-26 Herein, we conducted what 
to our knowledge is the first phase 1 clinical trial to date to 
evaluate metformin combined with CRT in patients with 
LAHNSCC.
The MTD for metformin could not be established 
reliably from the current study given that only 10 of the 
18 evaluable patients were able to tolerate metformin 
through a significant portion of CRT. However, 2550 mg 
daily was found to be the highest dose with the most tol-
erable profile in the current study, suggesting that it may 
be the most reliable dose for subsequent phase 2 studies. 
Given that DLTs were to be collected until 2 weeks after 
the completion of RT, this does limit the reliability of the 
full assessment of DLTs with the combination in the cur-
rent study. Patients experienced DLTs at dose levels 2 and 
3. Side effects predominantly involved the gastrointestinal 
tract and kidneys, and typically were related to dose. No 
deaths related to metformin were reported in the current 
trial. Overall, the combination was safe but with limited 
tolerability with CRT due to gastrointestinal toxicity.
The small number of patients included in the cur-
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draw conclusions regarding the efficacy of metformin. 
Nevertheless, the 2-year OS and PFS rates of 90% and 
85%, respectively, were found to improve when com-
pared with historical control rates of 80% and 65%, 
respectively. However, this finding could be influenced by 
the high prevalence of p16 positivity in the patient popu-
lation in the current study, which may have confounded 
the results. Metformin warrants further investigation in a 
phase 2 trial, but would be better tolerated in combina-
tion with less emetogenic systemic therapies.
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